185 related articles for article (PubMed ID: 12745061)
1. Antidyslipidemic action of fenofibrate in dyslipidemic-diabetic hamster model.
Rizvi F; Puri A; Bhatia G; Khanna AK; Wulff EM; Rastogi AK; Chander R
Biochem Biophys Res Commun; 2003 May; 305(2):215-22. PubMed ID: 12745061
[TBL] [Abstract][Full Text] [Related]
2. High fat fed hamster, a unique animal model for treatment of diabetic dyslipidemia with peroxisome proliferator activated receptor alpha selective agonists.
Wang PR; Guo Q; Ippolito M; Wu M; Milot D; Ventre J; Doebber T; Wright SD; Chao YS
Eur J Pharmacol; 2001 Sep; 427(3):285-93. PubMed ID: 11567659
[TBL] [Abstract][Full Text] [Related]
3. Free fatty acid metabolism during fenofibrate treatment of the metabolic syndrome.
Vega GL; Cater NB; Hadizadeh DR; Meguro S; Grundy SM
Clin Pharmacol Ther; 2003 Sep; 74(3):236-44. PubMed ID: 12966367
[TBL] [Abstract][Full Text] [Related]
4. Anti-hyperlipidemic and insulin sensitizing activities of fenofibrate reduces aortic lipid deposition in hyperlipidemic Golden Syrian hamster.
Srivastava RA; He S
Mol Cell Biochem; 2010 Dec; 345(1-2):197-206. PubMed ID: 20740305
[TBL] [Abstract][Full Text] [Related]
5. Antidyslipidemic potential of a novel farnesoid X receptor antagonist in a hamster model of dyslipidemia: Comparative studies of other nonstatin agents.
Shinozawa E; Amano Y; Yamakawa H; Haba M; Shimada M; Tozawa R
Pharmacol Res Perspect; 2018 Apr; 6(2):e00390. PubMed ID: 29541476
[TBL] [Abstract][Full Text] [Related]
6. Fenofibrate ameliorates diabetic and dyslipidemic profiles in KKAy mice partly via down-regulation of 11beta-HSD1, PEPCK and DGAT2. Comparison of PPARalpha, PPARgamma, and liver x receptor agonists.
Srivastava RA
Eur J Pharmacol; 2009 Apr; 607(1-3):258-63. PubMed ID: 19245804
[TBL] [Abstract][Full Text] [Related]
7. The high-fat high-fructose hamster as an animal model for niacin's biological activities in humans.
Connolly BA; O'Connell DP; Lamon-Fava S; LeBlanc DF; Kuang YL; Schaefer EJ; Coppage AL; Benedict CR; Kiritsy CP; Bachovchin WW
Metabolism; 2013 Dec; 62(12):1840-9. PubMed ID: 24035454
[TBL] [Abstract][Full Text] [Related]
8. Eburicoic Acid, a Triterpenoid Compound from Antrodia camphorata, Displays Antidiabetic and Antihyperlipidemic Effects in Palmitate-Treated C2C12 Myotubes and in High-Fat Diet-Fed Mice.
Lin CH; Kuo YH; Shih CC
Int J Mol Sci; 2017 Nov; 18(11):. PubMed ID: 29099085
[TBL] [Abstract][Full Text] [Related]
9. Lipase maturation factor 1: its expression in Zucker diabetic rats, and effects of metformin and fenofibrate.
Forcheron F; Basset A; Del Carmine P; Beylot M
Diabetes Metab; 2009 Dec; 35(6):452-7. PubMed ID: 19854668
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of the triglyceride- and cholesterol-lowering effect of fenofibrate in hyperlipidemic type 2 diabetic patients.
Forcheron F; Cachefo A; Thevenon S; Pinteur C; Beylot M
Diabetes; 2002 Dec; 51(12):3486-91. PubMed ID: 12453904
[TBL] [Abstract][Full Text] [Related]
11. Effect of liver fatty acid binding protein (FABP) T94A missense mutation on plasma lipoprotein responsiveness to treatment with fenofibrate.
Brouillette C; Bossé Y; Pérusse L; Gaudet D; Vohl MC
J Hum Genet; 2004; 49(8):424-432. PubMed ID: 15249972
[TBL] [Abstract][Full Text] [Related]
12. Effects of theabrownin from pu-erh tea on the metabolism of serum lipids in rats: mechanism of action.
Gong J; Peng C; Chen T; Gao B; Zhou H
J Food Sci; 2010 Aug; 75(6):H182-9. PubMed ID: 20722930
[TBL] [Abstract][Full Text] [Related]
13. Ragaglitazar: a novel PPAR alpha PPAR gamma agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models.
Chakrabarti R; Vikramadithyan RK; Misra P; Hiriyan J; Raichur S; Damarla RK; Gershome C; Suresh J; Rajagopalan R
Br J Pharmacol; 2003 Oct; 140(3):527-37. PubMed ID: 12970088
[TBL] [Abstract][Full Text] [Related]
14. Glycyrrhizic acid improved lipoprotein lipase expression, insulin sensitivity, serum lipid and lipid deposition in high-fat diet-induced obese rats.
Eu CH; Lim WY; Ton SH; bin Abdul Kadir K
Lipids Health Dis; 2010 Jul; 9():81. PubMed ID: 20670429
[TBL] [Abstract][Full Text] [Related]
15. Effects of fenofibrate on lipid parameters in obese rhesus monkeys.
Winegar DA; Brown PJ; Wilkison WO; Lewis MC; Ott RJ; Tong WQ; Brown HR; Lehmann JM; Kliewer SA; Plunket KD; Way JM; Bodkin NL; Hansen BC
J Lipid Res; 2001 Oct; 42(10):1543-51. PubMed ID: 11590209
[TBL] [Abstract][Full Text] [Related]
16. Effects of fenofibrate, gemfibrozil and nicotinic acid on plasma lipoprotein levels in normal and hyperlipidemic mice. A proposed model for drug screening.
Olivier P; Plancke MO; Marzin D; Clavey V; Sauzieres J; Fruchart JC
Atherosclerosis; 1988 Mar; 70(1-2):107-14. PubMed ID: 3162679
[TBL] [Abstract][Full Text] [Related]
17. Osthole ameliorates insulin resistance by increment of adiponectin release in high-fat and high-sucrose-induced fatty liver rats.
Qi Z; Xue J; Zhang Y; Wang H; Xie M
Planta Med; 2011 Feb; 77(3):231-5. PubMed ID: 20717873
[TBL] [Abstract][Full Text] [Related]
18. Hypolipidemic effect of the Chinese polyherbal Huanglian Jiedu decoction in type 2 diabetic rats and its possible mechanism.
Zhang XJ; Deng YX; Shi QZ; He MY; Chen B; Qiu XM
Phytomedicine; 2014 Apr; 21(5):615-23. PubMed ID: 24368167
[TBL] [Abstract][Full Text] [Related]
19. Cholesterol-lowering effects and potential mechanisms of different polar extracts from Cyclocarya paliurus leave in hyperlipidemic mice.
Jiang C; Wang Q; Wei Y; Yao N; Wu Z; Ma Y; Lin Z; Zhao M; Che C; Yao X; Zhang J; Yin Z
J Ethnopharmacol; 2015 Dec; 176():17-26. PubMed ID: 26477373
[TBL] [Abstract][Full Text] [Related]
20. A novel peroxisome proliferator-activated receptor alpha/gamma dual agonist demonstrates favorable effects on lipid homeostasis.
Guo Q; Sahoo SP; Wang PR; Milot DP; Ippolito MC; Wu MS; Baffic J; Biswas C; Hernandez M; Lam MH; Sharma N; Han W; Kelly LJ; MacNaul KL; Zhou G; Desai R; Heck JV; Doebber TW; Berger JP; Moller DE; Sparrow CP; Chao YS; Wright SD
Endocrinology; 2004 Apr; 145(4):1640-8. PubMed ID: 14701675
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
